Using Modern Imaging Technology

Learn More

With new, proprietary drug formulations

Learn More

To precisely treat late stage and metastatic cancer

Learn More

and to stimulate a natural, adaptive immune response.

Learn More

Intensity Therapeutics is creating a new, highly effective cancer treatment - in situ vaccination.

Learn More

News at Intensity Therapeutics

 

April 4, 2017

Intensity Therapeutics reports that INT230-6 Induces Protective T-Cell Immunity in preclinical models

Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary immune cell-activating cancer treatments, announced that tumor regression and immune activation data generated by the Company’s lead drug, INT230-6, will be presented in a poster session at the American Academy of Cancer Research (AACR) meeting on April 5, 2017.

 

June 26, 2016

Intensity Therapeutics, Inc. Raises $10 Million to Fund Clinical Supplies Manufacturing and Phase I/II Trials of INT230-6

Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary cancer immunotherapy products, today announced that it has secured $10 million in new capital from a Series A preferred stock financing.

 

June 2, 2016

Intensity Therapeutics Issued First US Patent for Immune-based Cancer Therapeutic Agents

Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary cancer immunotherapy products, today announced that the United States Patent and Trademark Office issued the Company US Patent 9,351,997.

 

Apr 22, 2016

SalvaRx announces US$2 million into Intensity Therapeutics

SalvaRx (LON: SALV), a biotechnology company focused on immunotherapy for cancer, is today pleased to announce its investment in US-based Intensity Therapeutics Inc. (“Intensity”), a private biotechnology company pioneering a new approach to treating solid tumours. The Company has invested US$2 million in cash for a 9.2% interest in Intensity (“the Investment”) as part of a Series A funding round.

 

Apr 19, 2016

Intensity Therapeutics reports that INT230-6’s Anti-cancer Mechanism is a Combination of Cell Death with Immune System Activation

Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary immune cell-activating cancer treatments, announced that Chief Medical Officer Dr. Ian B Walters will be presenting mechanism of action and other data in a poster session at the American Academy of Cancer Research (AACR) meeting on April 19, 2016. The research being presented indicates that INT230-6 induces significant cancer cell death in the tumor microenvironment. Thereafter, eradication of the tumor by INT230-6 requires T lymphocytes and leads to a potent and durable systemic anti-cancer T-cell-dependent immunity against the tumor.

 

Mar 6, 2016

Intensity Therapeutics Selected to Present at BioCentury Future Leaders Conference

Intensity Therapeutics, Inc., a privately-held biotechnology company developing proprietary immune cell activating anti-cancer drug products, announced that the Company has been selected to present at the 23rd annual Future Leaders in the Biotech Industry conference hosted by BioCentury. Chief Executive Officer Lewis Bender will present an update on the Company and the development status of INT230-6, an immune cell-activating anti-cancer drug candidate. The presentation will take place at 2:30pm ET on March 11, 2016 in room 402/403 at the Millennium Broadway hotel in New York City, NY.

 

Mar 3, 2016

Intensity Therapeutics Reports anti-Cancer Immunological Effect Generated by INT230-6

Intensity Therapeutics, Inc., a privately-held biotechnology company developing proprietary immune cell-activating cancer treatments, announced that preclinical research from the Company and its collaborators at the National Cancer Institute (NCI) were selected for oral presentation at two important upcoming congresses. The results demonstrate the ability of Intensity’s proprietary product, INT230-6, to create a robust anti-cancer immunological effect in a murine model of cancer.

 

Nov 5, 2015

Intensity Therapeutics Preclinical Results Show Anti- Cancer Synergy of INT230-6 with Anti-PD-1 Compounds

Intensity Therapeutics, Inc., a privately-held biotechnology company developing proprietary immune-based cancer therapy products, presented preclinical results from a study of the Company’s lead product, INT230-6, in combination with checkpoint inhibitors. The results show significantly increased antitumor response using a combination of INT230- 6 with an anti-PD-1 antibody compared to combined administration of anti-PD-1 and anti-CTLA-4 antibodies.

 

Oct 22, 2015

Intensity Therapeutics Forms Scientific Advisory Board Comprised of World-Leading Oncologists and Scientists

Intensity Therapeutics, Inc., a privately-held biotechnology company developing proprietary immune cell activating anti-cancer drug products, announced that Douglas Hanahan, Riccardo Lencioni and Mario Sznol would join the Company’s newly formed Scientific Advisory Board (SAB). These world-renowned scientists and physicians will provide research and development guidance on Intensity’s proprietary products and technology. The SAB members span a broad range of expertise relevant to Intensity’s approach including; immuno-oncology, clinical trial design, interventional oncology, tumor imaging, tumor microenvironment, cell regulation and cancer vaccination.

 

Oct 12, 2015

Intensity Therapeutics, Inc. CEO to Speak at the 10th Annual Value-Based Oncology Management Forum

Intensity Therapeutics has been invited to speak on Wednesday October 14 at CBI's 10th annual Value-Based Oncology Management Forum at the Warwick Allerton Hotel in Chicago. This conference brings industry and government representatives together in order for payers to understand the current practices of cancer care and treatment.

 

Oct 6, 2015

Kuala Innovations Limited invests in Intensity Therapeutics.

 

July 21, 2015

Batterson Venture Capital invests in Intensity Therapeutics.

 

April 16, 2015

Intensity Therapeutics, Inc., a privately-held biotechnology company developing proprietary immune-based cancer therapy products, announced that preclinical data using the Company's novel drug product, INT230-6, was selected for presentation at the 2015 American Association for Cancer Research (AACR) Annual Meeting.

 

Jan 5, 2015

Intensity Therapeutics, Inc. (private), developing novel cancer immunotherapy products, announced that President and CEO Lewis H. Bender will present at the 7th Annual Biotech Showcase & Investor Conference on Monday, January 12, 2015 at the Parc 55 Wyndham Hotel, 55 Cyril Magnin Street in San Francisco at 2:15PM (PST) in the Hearst Room (located on the 4th Floor).

 

Oct 9, 2014

Intensity Therapeutics, Inc.’s Research Selected for Presentation at the Annual National Cancer Institute Cancer Immunology and Immunotherapy Conference

Intensity Therapeutics, Inc., a privately-held biotechnology company developing proprietary cancer immunotherapy products, announced that preclinical data using the Company's novel drug product, INT230-6, was selected for a poster presentation at the National Cancer Institute’s annual Cancer Immunology and Immunotherapy Meeting.

 

Sep 2, 2014

Intensity Therapeutics, Inc. Appoints Ian B. Walters M.D., MBA as Vice President and Chief Medical Officer

Intensity Therapeutics, Inc., a privately-held specialty pharmaceutical company developing novel products to treat solid tumor cancers, announced today that Ian B. Walters M.D., MBA, has been appointed as Vice President, Clinical Development & Chief Medical Officer.

 

May 28, 2014

Intensity Therapeutics, Inc. Awarded Cooperative Research and Development Agreement from the National Cancer Institute

Intensity Therapeutics, Inc. (private) announced today that the Company established a cooperative research and development agreement (CRADA), with the National Institute of Health’s National Cancer Institute (NCI) Vaccine Branch. The research program will use Intensity's in situ chemovaccination technology.

 

May 7, 2014

Intensity Therapeutics, Inc. to Present at the 2014 NYBIO Annual Conference in New York

Intensity Therapeutics, Inc. (private) announced that its President and CEO, Lewis H. Bender, will present at the 2014 NYBIO Annual Conference Pitch and Partner Forum at 10:00PM on Wednesday, May 14, 2014 in the Tower West Room.

 

April 24, 2014

Intensity Therapeutics, Inc. to Participate on Cancer Panel at the Wharton DC Innovations Summit

Intensity Therapeutics, Inc. (private) announced that President and CEO Lewis H. Bender will participate in a panel discussion on Biotech Innovation in cancer at the Wharton Innovation Summit at 3:30PM on Wednesday, April 30, 2014.

 

March 26, 2014

Intensity Therapeutics looks to raise $7.5m to bring intratumoral chemo to clinical trials

As featured in Biopharm Insight. The company has raised $1.5m of its planned $9m target for its lead preclinical candidate, in intratumoral chemotherapy, said CEO Lewis Bender.

 

March 4, 2014

Intensity Therapeutics to Present at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum

Intensity Therapeutics, Inc. (private) announced today that President and CEO Lewis H. Bender will present at 2nd Annual Sachs Cancer Bio Partnering & Investment Forum at the New York Academy of Sciences (NYAS) on March 19, 2014.

 

Feburary 10, 2014

BioCentury's feature article on Intensity Therapeutics

Intensity Therapeutics featured as an Emerging Company in BioCentury.

 

November 14, 2014

Intensity Therapeutics, Inc. to Present at the Life Sciences Summit Conference

Intensity Therapeutics, Inc. (private) announced that President and CEO Lewis H. Bender will present at the Life Sciences Summit sponsored by Stoney Brook University on Wednesday, November 20, 2013 at the Convene located at 730 Third Avenue, on the third floor in New York City.

 

November 7, 2013

Intensity Therapeutics, Inc. (private) announced that the Company has been named a 2013 Tech Company to Watch by the Connecticut Technology Council. The Company was also selected to present at the 2013 Innovation Summit held in Wallingford, CT on November 7.

 

November 1, 2013

Intensity Presents at Landmark Angels Investor Conference

Intensity Therapeutics, Inc. (private) announced that President and CEO Lewis H. Bender will present at the Landmark Angels Investor Conference on Wednesday, November 6, 2013 at the Union League Club 38 East 37th Street in New York City.

 

September 9, 2013

Intensity Presents at RESI Conference

Intensity Therapeutics, Inc. (private) announced that President and CEO Lewis H. Bender will present at the Redefining Early Stage Investments (RESI) Conference on Monday, September 16, 2013 at the State Room, 60 State Street 33rd Floor, Boston MA.

 

May 23, 2013

Intensity Presents at NYBA Conference

Intensity Therapeutics, Inc. (private) announced that President and CEO Lewis H. Bender will present at the Annual New York Biotech Conference on Wednesday, May 29, 2013 at Marriott Marquis Hotel, in New York City.

 

March 24, 2013

Intensity designated a Qualified CT Business

Intensity Therapeutics, Inc. (private) announced the Connecticut Innovations approved the Company as a "Qualified Connecticut Business" (QCB).

 

March 12, 2013

Intensity Presents at Venture Summit 2013

Intensity Therapeutics, Inc. (private) announced today that President and CEO Lewis H. Bender will present at the Life Sciences Venture Summit on March 19, 2013 at the Digital Sandbox, 53 Broad Street, in New York City.

 

February 26, 2013

Intensity Raises Preseed Funding

Intensity Therapeutics, Inc. (private) announced the Company has raised over $225,000 in a preseed funding.

 

January 3, 2013

Intensity Presents at Biotech Showcase 2013

Intensity Therapeutics, Inc. (private) announced that President and CEO Lewis H. Bender will present at the 5th Annual Biotech Showcase & Investor Conference on Monday, January 7 at the Parc 55 Meridian Hotel, in San Francisco.

 

November 14, 2012

Intensity Executes Collaboration Agreement with the NIH

Intensity Therapeutics, Inc. (private) announced that the Company has established a collaboration agreement with the National Institute of Health’s National Cancer Institute (NCI).

 

 

For all media inquiries please contact: info@intensitytherapeutics.com

 

Contact Us


Intensity Therapeutics, Inc.
8 Wright Street, Suite 107
Westport, CT 06880


Tel. (203) 682-2434
Fax (203) 664-1051


info@intensitytherapeutics.com

 

Click here for career inquiries

Who we are

 

Intensity Therapeutics is a clinical development stage company.  We are seeking partnerships/investors interested in advancing the company’s anti-cancer platform technology and lead product INT230-6.

 

Click here for inquiries

News